4th CCP SUMMIT 2020

COMMERCIALIZING CONTINUOUS PROCESSING IN PHARMA

Embrace Innovations to Deliver a Quality & Affordable Product to Patients

January, 28-30, 2020 | Boston, USA

BOOK BY OCTOBER 4TH TO SAVE UP TO $900!

The Only Dedicated Community for Continuous Manufacturing Commercialization

Carla Luciani
Group Leader of Future Manufacturing Innovation, Associate Engineering Advisor
Eli Lilly & Co.

Bob Lenich
Director, Life Sciences Business
Emerson

Jon-Paul Sherlock
Global Technology Strategy Director
AstraZeneca

Manuel Osorio
Senior Scientist & Program Lead for Emerging Technologies, CBER
FDA

Douglas Hausner
Associate Director,
Rutgers University & C-SOPS

Nick Thomson
Senior Director, Chemical Research & Development
Pfizer Inc.

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

2020 PARTNERS

sartorius stedim biotech | Seeq | EMERSON | ASYMCHEM | Purolite® Life Sciences

Tel: +1 617 455 4188 Email: info@hansonwade.com **www.continuous-processing-pharma.com**

hansonwade

ABOUT CCP

Safety, Efficacy, Efficiency & Quality: Scaling Your Continuous Processing from Technology to Commercial Manufacturing

Since we embarked on the continuous manufacturing journey in 2017, we aim to help pharma and biotechs to embrace this emerging technology, in order to deliver a quality and affordable drug product for patients globally.

It is extremely encouraging to see our community expand over the years and now recognize us as the go-to meeting for the latest information of CM.

Proud to be the **only industry-led continuous manufacturing meeting** catering for **both small molecules and biologics**, we will continue to facilitate knowledge exchange.

Be part of the dialogue in January, 2020!

> "The conference was very thoughtfully put together with reasonable sized segments of presentations and a clear theme, with carefully designed networking activity interspersed in between"
>
> Senior Scientist, Eli Lilly

> "Each year the conference has top notch industry leaders in both the roles of conference chairs and presenters. The knowledge and quality of the talks are excellent"
>
> Principal Systems Manager, Waters Corp

WHAT'S NEW IN 2020?

FDA's CBER explains their newly established Advanced Manufacturing for Complex Biologics Products program – and how they can help you get early access for continuous manufacturing approvals

ICH Q13 steering committee reveals their latest draft guidance and how this will impact on your quality submission

Merck reveals how they built the business case for filing an NDA under continuous manufacturing, and how they leverage regulatory flexibility

Codiak Bioscience and **ImmunoGen** present their latest data on continuous bioprocessing – from exosomes to ADCs – what opportunities does CM offer over batch?

Eli Lilly and **Amgen** showcase their latest control strategy data and simulation of virtual plant, enabling you to have a tighter control strategy and quality assurance

In-depth Pre-Conference Focus Day and **Workshops** to give you a 360° view on CM process design, scale up and project implementation

YOUR CONTINUOUS MANUFACTURING EXPERT SPEAKERS

Manuel Osorio
Senior Scientist & Program Lead for Emerging Technologies
FDA/CBER

Ganapathy Mohan
Executive Director, Head of External Affairs (Quality)
Merck & Co., Inc.



Justin Moser
Director – Advanced Manufacturing Technology
Merck & Co., Inc.

Malcolm Berry
Founder
mbchemistryconsulting

Jana Spes
Head of Pharmaceutical Development & Manufacturing Sciences
Ironwood Pharmaceuticals

Jon-Paul Sherlock
Global Technology Strategy Director
AstraZeneca

Nick Thomson
Senior Director, Chemical Research & Development
Pfizer Inc.

Douglas Hausner
Associate Director
Rutgers University & C-SOPS

Sune Klint Anderson
Principal Scientist
Janssen R&D

Bob Lenich
Director, Life Sciences Business
Emerson

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

Carla Luciani
Group Leader of Future Manufacturing Innovation, Associate Engineering Advisor
Eli Lilly & Co.



Marcus Fiadeiro
Associate Director, Continuous Manufacturing
Sanofi



Bradley Campbell
Research Scientist
Eli Lilly & Co.

Klaus Kaiser
Head of Downstream Development
Bayer AG

Joon Chong Yee
Associate Director, Upstream Process Development
Codiak BioSciences



James Angelo
Scientist II
Bristol Myers-Squibb

Elçin Içten-Gençer
Senior Engineer, Pivotal Drug Substance Process Development
Amgen

Kaid Harper
Senior Scientist
AbbVie

Daniel Milano
Senior Engineer, Conjugation Process Development
ImmunoGen

Dave Berry
Manager of Complex Particles
CPI UK

YOUR CONTINUOUS MANUFACTURING EXPERT SPEAKERS



Nathan Domagalski
Senior Principal Scientist
Pfizer Inc.

Ru Zang
Associate Director
Mersana Therapeutics

Thomas de Beer
Head of Laboratory of Pharmaceutical Process Analytical Technology
University of Ghent



Lisa Graham
VP, Analytics Engineering
Seeq

Atul Dubey
Director, Pharmaceutical Continuous Manufacturing
US Pharmacopeia

Miguel Gonzalez
Senior Director, Chemical Engineering
Asymchem

Hans Johansson
Global Applications Director, Life Sciences,
Purolite

Thomas Erdenberger
Process Development Consultant
Sartorius Stedim Biotech

Ian Leavesley
President
Modern Consulting, LLC



Ernie Hillier
Founder
EJH Consulting

> "The conference covered a good range of CM topics, with good presenters in all sections I attended"
>
> Director, Alkermes

> "CCP Summit has been consistently providing the scientific community with a great forum to share knowledge and learn more from the continuous manufacturing network"
>
> Sr Director Chemical Engineering, Asymchem

PRE-CONFERENCE FOCUS DAY | TUESDAY | JANUARY 28, 2020

This focus day will encompass short presentations on regulatory affairs, CMC and continuous manufacturing business decisions. Through group discussions, you will be able to understand how to lead a successful CM project.

	8.30	**Registration & Welcome Coffee**
Atul Dubey Director, Pharmaceutical Continuous Manufacturing **US Pharmacopeia**	9.00	**US Pharmacopeia and ICH Q13 Quality Draft Guidance Updates** • Status update on draft guidance • The importance of defining a common quality framework globally to help promote CM development • The next phase and Q&A
Malcolm Berry Founder **mbchemistry-consulting**	9.30	**A Discussion of Selected Regulatory Feedback Ahead of and After Filing a Multistage Continuous Process to API** • The value of the pre-operational visit • Observations of common themes and differences between agencies • Feedback post file
	10.00	**Ice Breaking Session**
	10.30	**Coffee Break**
Ru Zang Associate Director **Mersana Therapeutics**	11.00	**When Should You Start Considering Continuous Manufacturing?** • FDA Perspective on biopharmaceutical continuous manufacturing • Evaluating your manufacturing option • Why should you consider continuous manufacturing as one option? • Process design and development – what are your options? Fed-Batch vs continuous manufacturing • Decision point before entering clinical manufacturing-When do you need to make the decision? • Other factors: in-house capability vs outsourcing?
	11.30	**Group Discussion & Feedbac**
	12.30	**Networking Lunch**
Jana Spes Head of Pharmaceutical Development & Manufacturing Sciences **Ironwood Pharmaceuticals**	13.30	**Continuous Manufacturing – Go or No Go?** • From product type to costs of goods – how do you draw up the business case to decide on manufacturing approach? • Pros and cons of batch vs CM • Scalability and investment requirements • Risks and timeline • The final steps of making the go/no go decision
Session Reserved for Spotlight Partner	14.00	**From Design to Building – What Does it Take to Commission a Successful Continuous Manufacturing Fleet?** • Project management to commission a multi-billion continuous manufacturing asset worldwide • Validate and filing challenges and lessons learned
	14.30	**Group Exercise to Draw Up Your Own Continuous Manufacturing Development Plan**
	15.30	**Discussion**
	16.00	**End of Focus Day**

"Conference was well run, great presentations and round table discussions. The networking was good, definitely talked with people whom I normally would not have"

Director of Innovations, Ferring

"It was a great and successful CM meeting, bringing both small molecules and biologics for knowledge sharing. I really enjoyed the panel and breakout discussions, and gained insights from fellow colleagues from other organizations!"

Head of Continuous Manufacturing Skills Center, Sanofi

PRE-CONFERENCE WORKSHOPS | TUESDAY | JANUARY 28, 2020

Workshop A 9.00 - 12.00

Process Design & Development: KPIs and CQAs of Continuous Manufacturing

Process design and development remain a critical element of a success continuous manufacturing. This session will be catered for **both small molecules and biologics** attendees, and through in-depth discussion and scenario case study, you will be able to apply the following after this short course:

- Apply QbD to process design and development for continuous manufacturing
- Understand the difference between legacy product and novel molecule filing
- Equip with transferrable skills between small molecules and biologics, and drug substance vs drug products
- Define your product's critical quality attribute and integrate this as part of your process design and development plan
- Verification is key: proof of concept and verification testing

Ian Leavesley
President
Modern Consulting, LLC

Joon Chong Yee
Associate Director, Upstream Process Development
Codiak BioSciences

Workshop B 13.00 - 16.00

Scaling Up Continuous Manufacturing – From Lab to Commercial Implementation

Over the last few years we have witnessed the maturity of continuous manufacturing with a lot of pilot projects now going through **scale-up, and from lab to commercial implementation**. This can obviously be a pivotal moment a milestone for the project team but can also be a challenging one.

Ernie is an experienced continuous manufacturing expert and he'll be leading this session to give you a practical step-by-step guide on how to execute this. Through open discussions and scenario-based exercise, you will be able to:

- Account for critical factors during the scale-up and commercialization
- Appreciate the differences and variables of CM in lab and commercial scale
- Engage and involve the right stakeholders to ensure project sponsorship and support
- Define the appropriate and optimal timeline for your project, as well as critical milestones you need to check in
- Re-assess if you are ready to scale up
- De-risk any potential pitfalls

Ernie Hillier
Founder
EJH Consulting

CONFERENCE DAY ONE | WEDNESDAY | JANUARY 29, 2020

7.30 **Registration & Welcome Coffee**

8.15 **Chair's Opening Remarks**

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

8.30 **Opening Address: The New Launch: CBER's Advanced Manufacturing for Complex Biologics Products**

- The newly created organization within CBER to support and promote emerging technologies adoption within pharma and biotech
- Gain early access to engage with the FDA to ensure a smooth drug development and approval process
- Dissecting the myths and misunderstandings of closed door operations
- Q&As

Manuel Osorio
Senior Scientist & Program Lead for Emerging Technologies
FDA/CBER

8.30 **Continuous Manufacturing as a default platform for Oral Solid Drug Products**

- Market activities in continuous manufacturing and evolving regulatory support
- The reality of a flexible Supply chain – and the impact of regulations
- How can a manufacturing leader anticipate a volatile drug development portfolio?

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

9.30 **The Possibility of End-to-End Implementation of Continuous Manufacturing – From Development to Supply**

- Merck's CM journey so far – how to realize CM platforms for oral small molecule drug products
- Can we introduce CM from development to supply? The importance of a business case to demonstrate value proposition
- Our pilot case study on batch vs. CM comparison
- Looking forward – what are the opportunities?

Justin Moser
Director – Advanced Manufacturing Technology
Merck & Co., Inc.

10.00 **Panel Discussion: Is Continuous Manufacturing for Legacy Product Only? Can we be Courageous and Use it for NDA?**

This year's panel discussion will be focused on discussing CM strategies and how they relate to:

- ***Streamlining process analytics:*** What is the role of process analytics for a legacy product and a new product? What role does the process analytics strategy play in the process verification strategy?
- ***Ensuring rapid 'fume hood to launch':*** How can thoughtfully designed processes and work spaces, along with modular equipment, support rapid development for an NDA? Does this approach impact a legacy product? How can we foster a culture of collaboration that recognizes how we work and where we work, as well as the importance of hardware and software to enable CM?
- ***Matching batch size to demand:*** What should be considered to achieve the ability to deliver supply small batches quickly and with consistent quality? What impact does an ever-changing supply chain have on the CM strategy for meeting current needs and project needs?
- ***Achieving stakeholder engagement:*** Who are the stakeholders and what matters to them when deciding whether to pursue a legacy product or an NDA approach for CM?

Led by:

Lisa Graham
VP, Analytics Engineeringa
Seeq

10.45 **Speed Networking & Morning Coffee**

CONFERENCE DAY ONE | WEDNESDAY | JANUARY 29, 2020

Small Molecules Stream

11.45 End-to-End Continuous Flow Chemistry Process to Increase Production Efficiency

Miguel Gonzalez, Senior Director, Chemical Engineering, **Asymchem**

12.05 Application of Continuous API Manufacturing Technologies at Pfizer

- The importance of quality by design in API development and manufacture
- The role of modelling in process development and design of continuous processes
- The application of modelling to the design of plug flow reactor and continuous stirred tank reactor processes
- Selected case histories to exemplify key points

Nathan Domagalski, Senior Principal Scientist, **Pfizer Inc.**

12.45 Networking Lunch

13.15 Flexible API Supply Technologies; Pfizer's Strategy for API Continuous Development and Manufacturing

- Roadmap to-date – the business case for continuous and our path to building capability
- Benefits of deploying continuous manufacturing for API to secure greater agility
- Our strategy for portfolio impact and development of a modular library of technologies
- Next steps

Nick Thomson, Senior Director, Chemical Research & Development, **Pfizer Inc.**

13.45 Innovation on OSD Continuous Manufacturing Platform

Session reserved for Program Partner

Biologics Stream

11.45 Towards Continuous Drying Technologies for Parenterals

- From continuous manufacturing drug product to assessing the possibility of continuous freeze drying
- Rational behind choosing this unit process - costs of goods, technology requirements and benefits
- Early lessons learned and next steps

Sune Klint Anderson, Principal Scientist, **Janssen R&D**

12.15 A Continuous and Controlled Pharmaceutical Freeze-Drying Technology for Unit Doses

- A continuous and controlled freeze-drying technology for unit doses to preserve biopharmaceuticals has been developed and will be presented
- How continuous freeze-drying technology offers clear advantages over current batch production such as cost reduction (up to 50%), track-and-trace product quality control at unit dose level, and a significant reduction of processing time (> 40 times faster, e.g. 1 hour instead of 5 days at a vial level), reduced need for clean room and a substantial sustainability gain.
- Results of feasibility studies using this new technology with different types of biopharmaceuticals

Thomas de Beer, Head of Laboratory of Pharmaceutical Process Analytical Technology, **University of Ghent**

13.15 Design of Jetted Protein A Resins for Continuous Chromatography

- Scalable, continuous 'Jetting' technology to produce beads with a narrow particle-size distribution
- Considerations of dynamic binding capacity (DBC), purification performance, cleaning in place (CIP) and fouling of chromatography resins
- Proven data to demonstrate improved process economics in commercial manufacturing

Hans Johansson, Global Applications Director, Life Sciences, **Purolite**

13.35 Sanofi's Continuous Manufacturing Journey Update – Achieving an End-to-End Integrated Continuous Bioprocessing

- Project update – the end goal of end-to-end integrated continuous bioprocessing, lessons learned so far?
- Sanofi's unique approach of multiple sites CM operations – business case and advantages
- Empowering each site with their own capability and facilitating knowledge and tech transfer
- Looking beyond and opportunities ahead

Marcus Fiadeiro, Asssociate Director, Continuous Manufacturing, **Sanofi**

CONFERENCE DAY ONE | WEDNESDAY | JANUARY 29, 2020

14.15 Commercializing New Chemical Technologies in Flow

- Abbvie's approach toward implementing flow technology
- Scaling and commercializing visible light photoreactors
- Scaling and commercializing electrochemical reactors

Kaid Harper, Senior Scientist, **AbbVie**

14.05 Continuous Bioprocessing for Exosomes Manufacturing – Upstream Case Study from Codiak Biosciences

- Case study for scaling up a perfusion process for exosome manufacturing to clinical manufacturing scale
- Comparison of productivity and product quality attributes of exosome manufacturing in fed-batch and perfusion modes
- Implementation of process analytical tools to achieve steady state VCD profiles in perfusion process

Joon Chong Yee, Associate Director, Upstream Process Development, **Codiak Biosciences**

14.45 Afternoon Networking Tea & Poster Session

15.30 Creating a Common Language and Framework to Support Continuous Manufacturing Globally

- Product quality and CMC definition
- ICH Q13 draft guidance – what is the status quo and where are we with the guidance development?
- Continuous manufacturing in GMP environment
- How to harmonize and standardize across the world?
- What's next?
- Q&A

Ganapathy Mohan
Executive Director, Head of External Affairs (Quality)
Merck & Co., Inc.

16.00 Continuous Downstream Processing – Where Are We in Regard of Comparability and Regulatory Challenges?

- Reason for continuous manufacturing? From cost efficiency, reliability to scalability and facility footprints for manufacturing of biopharmaceuticals
- How can continuous manufacturing better support demand changes from clinical to launch and for volatile market dynamics?
- Gap analysis
- Design aspects
- Product comparability
- Transfer from batch to continuous
- Regulatory aspects
- Illustrate comparability of CM vs. batch processing in a side-by-side approach covering process information, real time analysis and quality data from intermediates and final drug substance of an antibody product

Kaiser Klaus
Head of Downstream Processing
Bayer AG

16.30 Roundtable Discussion:

- How to handle a volatile pipeline and commit to manufacturing decisions?
- Exploring continuous manufacturing for NDA and legacy products
- Setting KPIs for CM – MSAT vs. Manufacturing vs. Plant/ Site Heads

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

17.15 Chair's Closing Remarks & End of Day 1

17.30 Poster Session

CONFERENCE DAY TWO | THURSDAY | JANUARY 30, 2020

8.00 **Welcome Coffee**

8.45 **Chair's Opening Remarks**

Lawrence de Belder
Senior Principal Scientist Continuous Manufacturing
Janssen

9.00 **Opening Address: Small Molecule Design & Development Approach at Eli Lilly in Driving Future Manufacturing Platforms**

- From risk averse to risk takers – time for innovations and re-defining business case
- Impacts and trends in CMC – how to prioritize?
- The need to exploit flexible manufacturing platforms: Continuous processing initiatives
- Challenges: How will the industry look in 10 years? How do we adapt to new modalities?
- Case studies

Carla Luciani
Group Leader of Future Manufacturing Innovation, Associate Engineering Advisor
Eli Lilly & Co.

9.30 **AstraZeneca's Journey in Continuous Manufacturing – From Technology Strategy to Pre-Competitive Collaboration**

- How should you define manufacturing technology strategy when pipeline is becoming more volatile and innovation is happening too fast?
- Business case and rational behind continuous manufacturing: roadmap from feasibility study to commitment and commercialization
- Embracing innovations and external collaboration to accelerate scientific development and share risks

Jon-Paul Sherlock
Global Technology Strategy Director
AstraZeneca

10.00 **The Future – Automated Continuous Manufacturing**

- Manufacturing 4.0 – what does it look like?
- Why is automated and connected manufacturing important for continuous manufacturing?
- Opportunities and challenges

Bob Lenich
Director, Life Sciences Business
Emerson

10.30 **Morning Coffee**

Small Molecules Stream

11.15 **Implementation of Continuous Pharmaceutical Technology Through Open Innovation in the UK Catapult Network**

- The value of leveraging pre-competitive Open Innovation to drive the implementation of continuous technology in oral solid dose pharmaceutical manufacture
- Specific examples of continuous wet granulation and continuous direct compression to exemplify key OSD production processes
- The use of model based predictive control and the implementation of multiple process analytical technology (PAT) sensors to drive high quality pharmaceutical products

Dave Berry, Manager of Complex Particles, **CPI UK**

Biologics Stream

11.15 **Perspectives on Intensified & Continuous Processing**

Thomas Erdenberger, Process Development Consultant, **Sartorius Stedim Biotech**

CONFERENCE DAY TWO | THURSDAY | JANUARY 30, 2020

11.45 Real Time Product Release – What's the Strategy and Best Practice?

- Overview of RTPR technologies and experience on collaboration with Janssen's approved product
- What if it's a low dose PAT? Can you push the limit and demonstrate product quality?
- How can we define best practice to provide better guidance for continuous manufacturing?

Douglas Hausner, Associate Director, **Rutgers University & C-SOPS**

11.35 From Proof of Concept to Scaling Up: ImmunoGen's Story in Continuous Bioprocessing

- Why ImmunoGen chooses to develop continuous bioprocessing?
- Developing in-house process understanding and technologies for continuous manufacturing of ADCs: risks, challenges and opportunities
- Case study to demonstrate the viability and benefits of using continuous bioprocessing vs batch
- The hurdle of scaling up and outsourcing – what are we looking for?

Daniel Milano, Senior Engineer, Conjugation Process Development, **ImmunoGen**

12.05 Scale-Up Design and Optimization for a Semi-Continuous Downstream Process

- A model-assisted design methodology for intensified downstream unit operations will be discussed
- Challenges and lessons learned bringing more complex automation and process modes to clinical manufacturing level
- Outlook of intensified manufacturing – reduced processing cadence and increased throughput for smaller facility footprints

James Angelo, Scientist II, **Bristol-Myers Squibb**

12.35 Networking Lunch

13.35 Speed Learning: Delegates can choose to rotate between these 2 topics and we will select a hosted leader to facilitate discussions.

Topic 1: Partnership with CMO

- Capability and competence of CM from CMO
- A hand in hand approach – forming collaborative partnership with CMO and CDMO earlier on
- Overcoming capacity problems: invest in CM from today

Topic 2: Moving Towards a GMP Environment

- Establish GMP framework for continuous manufacturing
- Harmonizing industry standards to ensure product quality and boosting confidence

14.25 Implementing Robust Process Analytic Tools to Ensure Quality from Continuous Processes

- Online, at-line, and offline HPLC to support decision making during production
- Case Study of PAT tools utilized throughout a process
- Integration of Data Tools to make the data meaningful to the entire process team

Bradley Campbell
Research Scientist
Eli Lilly & Co.

14.55 Towards End-to-End Continuous Manufacturing – Development of a Virtual Plant

- End-to-end continuous manufacturing process supported by integrated systems-based modelling
- Virtual plant enables simulation of multi-step chemical synthesis and purification steps
- *In silico* characterization used to improve process robustness and develop process control strategy to drive product quality
- Building capability of tech transfer using this model
- Project collaboration with MIT

Elçin Içten-Gençer
Senior Engineer, Pivotal Drug Substance Process Development
Amgen

15.25 Chair's Closing Remarks & End of Summit

Lawrence de Belder
Senior Principal Scientist
Continuous Manufacturing
Janssen

WHY PARTNER WITH US?

Pharma and biotech are seeking partnerships and support to accelerate the switch from batch to continuous processing. If you have a unique and innovative platform or solution that can help, we would love to partner with you.

Through our bespoke partnership options, we can help you become a continuous manufacturing influencer and thought leader by sharing the stage with our industry experts.

MEET 130+

SENIOR AND COMMITTED CM LEADERS THIS JANUARY!

WHO WILL YOU MEET?

ATTENDEES' SECTORS*

Pharma & Biotech	56%
Solution Providers & CMOs	34%
Regulatory Agency, Academics & Research Institutions	10%

ATTENDEES' SENIORITY*

Director	31%
Manager & Team Leader	22%
Scientist	17%
CxO & VP	15%
Head	10%
Other	5%

ATTENDEES' JOB FUNCTIONS*



Process Design & Development	31%
Manufacturing	26%
Commercial	18%
Scientist	10%
PAT	10%
Regulatory, QA, CMC	5%

*Based on 2019 attendees' profile

SNAPSHOT OF PREVIOUS ATTENDEES

agenus, Bayer, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, FDA, Genentech, gsk, insmed, janssen, BARDA, LEO, MERCK, MIT Massachusetts Institute of Technology, SANOFI, FERRING PHARMACEUTICALS, Takeda, VERTEX, REGENERON

Sam Berrill
Partnerships Director
E: Sponsor@hansonwade.com
T: 1 617 455 4188

2020 Partners

Emerson
Expertise Partner
www.emerson.com

Life Sciences manufacturers strive to create innovative and reliable products that help people lead healthier lives. Emerson has the automation expertise and technology to solve your greatest cGMP manufacturing challenges and create effective solutions for improving your data management, real-time product quality, reliability, and operating costs. From design to implementation and startup to on-going optimization, rely on Emerson to stay competitive in a global economy.

Seeq®
Hosting Partner
www.seeq.com

Seeq® empowers process manufacturers to rapidly investigate and share insights from data in historians, IIoT platforms, and web services as well as contextual data in manufacturing and business systems. Seeq's extensive support for time series data and its challenges gives organizations more value from data already collected and accelerates analyses. Powered by innovations in big data and machine learning technologies, Seeq helps organizations turn data into insights that drive collaboration, process improvement, and profitability.

Sartorius Stedim
Program Partner
www.sartorius.com

Sartorius Stedim Biotech delivers and implements rapid and cost-effective Biomanufacturing solutions from early phase development through scale-up to commercial manufacturing. Benefit from the most comprehensive bioprocess technology portfolio coupled with our expertise in single-use bioprocess engineering. Our global bioprocess teams are available to discuss your process development and manufacturing requirements.

Asymchem
Program Partner
www.asymchem.com

Asymchem is a leading CDMO which supports Western innovator programs, from preclinical development through commercial production. We offer a range of services; operating an unmatched suite of manufacturing technologies that include continuous process chemistry, biocatalysis, and other capabilities which improve robustness and safety, while reducing risk, waste, and cost. Founded in 1995, our 7 China sites were built from the ground up per Western standards, are fully cGMP compliant, and are routinely agency inspected.

Purolite Life Sciences
Program Partner
www.purolite.com

Purolite Life Sciences brings Purolite's innovative thinking and distinguished history of resin technology expertise to the global Life Sciences marketplace. Over three decades, Purolite has grown into the world's premier resin technology manufacturer and innovation leader, with production plants and advanced research labs across the globe.

READY TO REGISTER?

Team Discounts*

- 10% discount – 2 & 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5+ delegates

CCP 2020 Pricing

Industry Pricing - Drug Developer (Pharma & Biotech)	Register & Pay before Friday, October 4, 2019	Standard	On the door
Conference + 2 Workshops OR Focus Day	$3,197 **(Save $900)**	$3,797 **(Save $300)**	$4,097
Conference + 1 Workshop	$2,798 **(Save $700)**	$3,398 **(Save $100)**	$3,498
Conference Only	$2,299 **(Save $600)**	$2,899	$3,099
Pre-conference Focus Day		$1,198	
Workshop (Each)		$599	

Vendor Pricing - Equipment Provider, CMO, Consultancy & any CM Providers	Register & Pay before Friday, October 4, 2019	Standard	On the door
Conference + 2 Workshops OR Focus Day	$4,097 **(Save $900)**	$4,697 **(Save $300)**	$4,997
Conference + 1 Workshop	$3,698 **(Save $700)**	$4,298 **(Save $100)**	$4,398
Conference Only	$3,199 **(Save $600)**	$3,799	$3,999
Pre-conference Focus Day		$1,198	
Workshop (Each)		$599	

*Special academic rate available upon request

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

3 Easy Ways To Book

www.continuous-processing-pharma.com/take-part/register/

Email: info@hansonwade.com

Tel: +1 617 16 455 4188

THE COLONNADE
120 HUNTINGTON AVENUE
BOSTON, MA
USA

FOR FURTHER INFORMATION VISIT:
HTTPS://WWW.COLONNADEHOTEL.COM